Is Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Ironwood Pharmaceuticals, Inc. at current levels.
A single-drug cash machine trading at 2.4x forward earnings with a binary apraglutide call option the market refuses to price.
Where IRWD is headed
By late 2027, Ironwood is two companies sitting inside one ticker. The first is the Linzess royalty machine, still throwing off roughly $50-70M a year in free cash flow from the AbbVie partnership, a stable annuity that the market is currently valuing at less than four years of forward earnings. The second is the apraglutide story, a long-acting GLP-2 analog targeting short bowel syndrome with intestinal failure, a tiny patient population (around 18,000 in the US) where the existing standard of care, Takeda's Gattex, generates over $800M annually at peak with daily injections. Apraglutide is once-weekly. If the label lands and reimbursement follows, this is not a niche drug, it is a category replacement.
Read the full Compass Direction on IRWD
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $3.22).
See the full IRWD analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Ironwood Pharmaceuticals, Inc. at current levels. A single-drug cash machine trading at 2.4x forward earnings with a binary apraglutide call option the market refuses to price.
What is IRWD's Compass Score?
Ironwood Pharmaceuticals, Inc. scores 82/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for IRWD?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the IRWD page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.